CD47 and neoplasm: A few ideally designed BsAbs have been developed, such as IBI322 for CD47/PD-L1, IMM0306 for CD47/D20 and IMM2902 for CD47/Her2, which can preferentially bind to CD47 on tumor cells with the help of higher affinity of the bi-specific molecules for another tumor target, effectively inhibiting CD47-SIRPα signal and triggering strong tumor cell phagocytosis in vitro, but only with minimal impact on CD47 single positive cells such as human RBCs.